Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug:121:157-160.
doi: 10.1016/j.ijid.2022.05.001. Epub 2022 May 6.

Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy

Marta Colaneri  1 , Nicolò Amarasinghe  2 , Leonardo Rezzonico  2 , Teresa Chiara Pieri  2 , Emilio Segalini  2 , Margherita Sambo  2 , Silvia Roda  2 , Federica Meloni  3 , Marilena Gregorini  4 , Teresa Rampino  4 , Stefano Pelenghi  5 , Alessandra Ricciardi  2 , Raffaele Bruno  6
Affiliations
Observational Study

Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy

Marta Colaneri et al. Int J Infect Dis. 2022 Aug.

Abstract

Objectives: The effectiveness of a 3-day course of remdesivir to prevent severe disease in patients with COVID-19 who received solid organ transplant (SOT) is unknown. We wanted to study the efficacy of this therapeutic option in patients with COVID-19 who received SOT in preventing both hospitalizations for outpatients and clinical worsening due to COVID-19 for those already hospitalized for other reasons.

Methods: This is a single-center, retrospective, observational study conducted in the Fondazione IRCSS Policlinico San Matteo of Pavia, Northern Italy. We extracted all the data of patients with COVID-19 receiving SOT who received and did not receive pre-emptive remdesivir between December 23, 2021, and February 26, 2022. We used a Cox proportional hazard model to assess whether receiving pre-emptive remdesivir was associated with lower rates of hospitalization.

Results: A total of 24 patients who received SOT were identified. Among these, seven patients (29, 1%) received pre-emptive remdesivir, whereas 17 (70, 9%) patients did not. Receiving remdesivir significantly reduced the hospitalization rate in outpatients who received SOT and the clinical worsening of the condition of already hospitalized patients who received SOT (hazard ratio 0.05; confidence interval [0.00-0.65], P-value = 0.01).

Conclusion: In our cohort of patients infected with SARS-CoV-2 who received SOT, pre-emptive remdesivir was effective in reducing the hospitalization rate due to COVID-19 and in preventing the clinical worsening of the condition of patients who received SOT who were hospitalized for reasons other than COVID-19.

Keywords: 3-day course remdesivir; COVID-19; Solid organ transplant recipients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cox regression model shows reduced hospital admission at 28 days from the positivization of reverse transcription polymerase chain reaction (RT-PCR) nasal swab for SARS-CoV-2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. AIFA, AIFA statement. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pd..., 2022. (accessed 4 March 2022).
    1. Beigel John H, Tomashek Kay M, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed
    1. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305–315. - PMC - PubMed
    1. Heil EL, Kottilil S. The goldilocks time for remdesivir — is any indication Just Right? N Engl J Med. 2022;386:385–387. - PMC - PubMed
    1. National Institutes of Health, COVID-19 treatment guidelines: clinical spectrum of SARS-CoV-2 infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinicalspectrum..., 2022a. (accessed 4 March 2022).

Publication types